Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Abcellera, Apotex, Atyr, Axcella, Biocryst, Gri, Immix, Kaleibe, Nexcella, Nimble, Oxford Biomedica, Phoremost, Poolbeg, Praxis, Psyence, Qrons, Qu, Replay, Selecta, Sio, Sumitomo, Teva, Thinkcyte, UCB, Urica, Valbiotis, Vallon, Vanda, Woodward.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Actinogen, Alto, Avidity, Catalym, Dermaliq, Ellipses, Epicentrx, Imaginab, Geneos, Genprex, Icosavax, Irlab, Kymera, Moonlake, Oxurion, Passage, Precision, Quoin, Recbio, Splisense, Tracon, Ultimovacs.

Additional early-stage research and drug discovery news in brief, from: Dyadic, Nuvalent.

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bittium, Quantumdx.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Bioxytran, Eva, Exicure, Harrow Ipsen, Lilly.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Brainstorm, Evergreen, Galera, Ideaya, Janssen, Medivir, Pfizer, Recce, Sobi, Vertex.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Asieris, Astrazeneca, Biosion, Calidi, Calliditas, Glycotope, Immunogen, Lantern, Sosei, Therabest, Viatris, Zyversa.

The National Center for Global Health and Medicine (NCGM) and Tokyo Medical and Dental University have divulged 3C-like protease (3CLpro) (SARS-CoV-2) inhibitors reported to be useful for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections (COVID-19).